SEP 02, 2015 3:00 PM PDT

Impact of the cobas Liat® Flu Assay on Clinical Decision Making in the Emergency Department Setting (Clade Study Group)

Presented at: Microbiology
Speaker
  • Assistant Professor, Division of Infectious Diseases, Department of Pathology & Laboratory Medicine, University of Minnesota, and Director of Clinical Microbiology, Hennepin Medical Center
    Biography
      Dr. Glen Hansen is an Assistant Professor of Medicine in the Division of Infectious Diseases and the department of Pathology & Laboratory Medicine at University of Minnesota. He is the medical director for the clinical microbiology and molecular diagnostics laboratory at Hennepin County Medical Center HCMC The Clinical Microbiology laboratory is a full-service microbiology including areas of virology, mycology, mycobacteriology, bacteriology, parasitology and molecular diagnostics. He graduated from The University of Saskatchewan and Royal University hospital with a PhD in clinical microbiology. He has formal fellowship training in molecular diagnostics from New York Public Health Research Institute (PHRI) and clinical and medical microbiology from the University of Washington. He is the former director of microbiology and molecular Diagnostics at Oregon Medical/Peace Health laboratories in Eugene Oregon and has been the director of microbiology and molecular diagnostics at HCMC since 2006.

    Abstract

    Respiratory viral infections remain a leading cause of medical visits and can contribute significantly to morbidity and mortality. Influenza, together with pneumonia, is the leading infectious cause of death in Canada and the United States, and is of particular concern especially in individuals with secondary risk factors. As "influenza season" approaches each year, hospitals and healthcare organizations review and update testing algorithms in attempts to maximize clinical useful testing, staffing issues, sensitivity, and rising health care costs. Despite decades of diagnostic research into laboratory and clinic based influenza testing, no one single diagnostic algorithm has emerged as a one size-fits-all strategy. Clinical decision making and subsequent patient management for patients who present to busy emergency departments during flu season is not always straight forward. Recently the COBAS LIAT Influenza assay was recently approved by the FDA for diagnosis of Influenza A/B virus. The test represents among the first truly rapid multiplex molecular PCR-based assays that can simultaneously detect and discriminate influenza A and influenza B RNA in nasopharyngeal specimens. While the prospects of reliable rapid influenza diagnostics have been examined before, few studies have attempted to correlate in real time the immediate impact of influenza assays, and no study assessing the clinical utility of LIAT during influenza season has been performed to date. Objectives: 1. Introduce the historical challenges of test options for influenza testing in hospital settings 2. Describe the performance and test characteristics of the Cobas® Liat influenza A/B assay on emergency department patients who presented with influenza-like-illness during the 2015 influenza season 3. Demonstrate the impact that rapid reliable influenza testing within emergency department settings have on patient management


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    JUN 09, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    AUG 18, 2020 10:00 AM PDT
    C.E. CREDITS
    AUG 18, 2020 10:00 AM PDT
    DATE: August 18, 2020 TIME: 10:00am PT Get deeper understanding of gene expression patterns by using assays that retain spatial organization at single cell resolution! Come learn about the n...
    Loading Comments...
    Show Resources
    Attendees
    • See more